Description:
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1
GLP-1 agonists were approved by the FDA for weight loss in late 2014. It's a newer class of drugs better known for its ability to improve blood sugar control. These medications were actually designed to treat type II diabetes, but some have also been FDA approved to treat weight loss. The GLP-1 agonists we work with are called Semaglutide & Tirzepatide. Tirzepatide is known as Mounjaro.Semaglutide is also known Ozempic or Wegovy,which is dosed at 0.5-2.4mg per week,but we only can supply Semaglutide powder.